Verition Fund Management LLC Provention Bio, Inc. Transaction History

Verition Fund Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.52 - $10.57 $128,589 - $300,705	-28,449 Reduced 3.28%	838,716 $8.87 Million
Q3 2022 Nov 14, 2022	SELL	$3.43 - $5.62 $320,012 - $524,334	-93,298 Reduced 9.71%	867,165 $3.9 Million
Q2 2022 Aug 15, 2022	SELL	$3.65 - $7.3 $460,374 - $920,749	-126,130 Reduced 11.61%	960,463 $3.84 Million
Q1 2022 May 13, 2022	SELL	$3.4 - $7.88 $1.38 Million - $3.2 Million	-405,971 Reduced 27.2%	1,086,593 $7.95 Million
Q4 2021 Feb 14, 2022	BUY	$5.59 - $7.39 $4.34 Million - $5.74 Million	776,835 Added 108.54%	1,492,564 $8.39 Million
Q3 2021 Nov 15, 2021	BUY	$5.66 - $8.33 $3.97 Million - $5.85 Million	702,011 Added 5117.44%	715,729 $4.58 Million
Q2 2021 Aug 16, 2021	BUY	$6.71 - $11.04 $92,047 - $151,446	13,718 New	13,718 $116,000
Q2 2020 Aug 14, 2020	SELL	$7.81 - $17.0 $266,508 - $580,108	-34,124 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$5.42 - $17.75 $442,342 - $1.45 Million	-81,613 Reduced 70.52%	34,124 $314,000
Q4 2019 Feb 14, 2020	SELL	$5.84 - $14.9 $775,084 - $1.98 Million	-132,720 Reduced 53.42%	115,737 $1.72 Million
Q3 2019 Nov 14, 2019	BUY	$6.83 - $13.0 $1.7 Million - $3.23 Million	248,457 New	248,457 $1.7 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.